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ABSTRACT 
Arteriosclerosis is a degenerative process that is physiological in aging but can be 
accelerated  by  number  of  risk  factors,  such  as  hypertension,  diabetes,  obesity, 
smoking, familial history. Healthy vessel walls harbour vascular smooth muscle 
cells,  fibroblasts,  endothelial  cells,  whereas  in  arteriosclerotic  vessels 
inflammatory cells such as activated macrophages are also present. The biology of 
all these cells is tuned by calcium, that regulates both acute and adaptive, chronic 
events.  Calcium  signalling  plays  an  important  role  in  the  regulation  of  cell 
proliferation through the crosstalk between multifunctional Calcium-Calmodulin 
dependent kinases (CaMKs) and a number of other signalling pathways, such as 
Erk. Nevertheless, how these cellular pathways interact with each other has yet to 
be  investigated.  Our  recent  studies  demonstrate  that  a  murine  model  lacking 
CaMKIV  presents  early  onset  arteriosclerosis,  as  well  as  increased  CaMKII 
activity in selected cell types, thus implying a role for calcium signaling in the 
process. The recent genome-wide analysis of the Framingham Heart Study 100K 
Project shows an association between elevated diastolic blood pressure and the 
rs10491334 T/C Single Nucleotide Polymorphism of human CaMKIV gene. This 
finding suggests for this kinase, whose expression was once thought to be confined 
to  the  nervous  tissue,  a  yet  undisclosed  role  in  vascular  responses.  We  also 
obtained evidences of the existence of a crosstalk between CaMKII and CaMKIV, 
involved in the regulation of cell cycle progression. These results indicate a novel 
interplay between CaMKs, that has never been investigated in the modulation of 
cell  proliferative  responses,  and  might  have  tremendous  implications  in 
arteriosclerosis. 
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1. INTRODUCTION
1.1 The Calcium/Calmodulin dependent Kinases family (CaMKs)
Calcium (Ca2+) is an ubiquitous intracellular second messenger that regulates cell 
processes including proliferation,  development,  motility,  secretion,  learning and 
memory.  Several  stimuli,  such  as  hormones,  growth  factors,  cytokines,  and 
neurotransmitters induce changes in the intracellular levels of Ca2+. A resting cell 
typically  has  a  cytosolic  Ca2+  concentration  of  100  nM,  a  concentration 
approximately 20,000-fold lower than that of extracellular Ca2+ (Hook and Means, 
2001). Cells control cytoplasmic  Ca2+  levels through ATP-dependent  Ca2+ pumps 
that transport Ca2+ into the two major Ca2+ stores: the endoplasmic reticulum (ER) 
and the extracellular space. Different signals stimulate either waves or spikes of 
increased  intracellular  Ca2+ and  the  origin  of  Ca2+ depends  upon the  stimulus. 
Receptor  tyrosine  kinases  and  G-protein-coupled  receptors  classically  increase 
Ca2+ levels by producing IP3, which induces Ca2+ release from the ER via the IP3 
receptor (Berridge, 1993; Berridge and Irvine, 1989). Similarly, cyclic ADP ribose 
can release Ca2+ from intracellular stores. Ligand gated ion channels and voltage-
dependent ion channels in the plasma membrane, however, initiate Ca2+ entry via 
extracellular  stores.  Subsets of each of these types  of channels  have also been 
shown to cause Ca2+ release from intracellular stores via either the IP3 receptor or 
the ryanodine receptor. The most ubiquitous and abundant protein that serves as a 
receptor  to  sense  changes  in  Ca2+ concentrations  is  Calmodulin  (CaM),  thus 
mediating the role as second messenger  of this  ion.  CaM is a 148–amino acid 
protein (16,680 daltons)  comprised  of 4 helix-loop-helix  protein folding motifs 
called EF hands, with two making up the N-terminal domain and two comprising 
the C-terminal domain (Tjandra et al., 1995). Each of the four EF hands binds one 
Ca2+  ion.  The binding affinity to each site is approximately 1 uM, although the 
pair of EF-hands in the N terminus is of slightly lower affinity than the pair in the 
C  terminus.  When  the  four  binding  sites  are  filled,  CaM  undergoes  a 
conformational change exposing a flexible eight-turn a-helix, which separates the 
hydrophobic  pockets  that  form  in  each  of  the  globular  ends  of  the  protein. 
Calmodulin thus becomes “loaded” to interact with one of its many target proteins 
in the cell. This target protein interaction, while usually of high affinity, is rapidly 
reversible upon a decline in  Ca2+  concentration (Means, 2000). Among the many 
Ca2+/CaM  binding  proteins  activated  by  CaM,  there  is  a  family  of 
serine/threonine protein kinases called  Ca2+/CaM-dependent protein kinases. This 
family includes kinases such as phosphorylase kinase, myosin–light chain kinase 
(MLCK), and CaM kinases I,  II,  III,  and IV (Means, 2000). These kinases are 
grouped according to whether they are dedicated kinases having a single substrate 
(phosphorylase kinase, CaM KIII, and MLCK) or whether they are multifunctional 
2
(CaM KI, II, and IV) and have several substrates. The general structure of CaMKs 
(figure 1.1) includes an N-terminal kinase domain, an autoregulatory domain, an 
overlapping CaM-binding domain and, in phosphorylase kinase and CaMKII, a C-
terminal association domain that is essential for multimerization and targeting.
Figure 1.1 | Schematic diagram of the CaM kinases highlighting their domain structure. 
The  sequences  of  the  overlapping  autoinhibitory  and  CaM-binding  domains  of  CaM  KI  and 
homologous regions of CaM KII and IV are shown. Within the catalytic domain of CaM KI and IV 
is the activation loop containing the T residues phosphorylated by CaM KK. The C-terminal NLS 
of CaM KII is shown with the S phosphorylated by CaM KI and IV specified with an asterisk.  
(Hook and Means, 2001)
The activation process involves a conformational change of the target protein upon 
binding of calcium/CaM to a short region known as the CaM binding domain. In 
the  case  of  CaM-dependent  kinases  such  as  myosin-light  chain  kinase  or  the 
multifunctional CaM kinases I, II and IV, an autoinhibitory domain, interacts with 
the  catalytic  domain  keeping  the  enzyme  inactive  at  resting  calcium  levels. 
According  to  this  ‘intrasteric  inhibition’  model  (Cruzalegui  et  al.,  1992), 
calcium/CaM binding to a region adjacent to the autoinhibitory domain causes a 
change in conformation that permits access of peptide substrates and adenosine 
triphosphate  (ATP)  to  the  catalytic  domain.  In  this  manner,  CaM-dependent 
kinases can rapidly sense elevations of intracellular calcium becoming active as 
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calcium-bound CaM binds to them. In addition, some of these enzymes are also 
equipped with mechanisms that enable them to prolong their activity after calcium 
has returned to basal levels. This form of ‘molecular memory’ is best documented 
for CaM kinase II, a multimeric enzyme composed of at least 10 subunits. Each 
one of the subunits is a 50–60-kDa polypeptide containing an N-terminal catalytic 
domain, a central autoinhibitory and CaM binding region and a C-terminal domain 
responsible  for  multimerization  and  intracellular  localization.  The  unique 
multimeric structure of CaM kinase II allows very rapid trans-phosphorylation of 
subunits within the complex. As a consequence of trans-phosphorylation, a subunit 
acquires Ca2+/CaM-independent activity (Miller and Kennedy, 1986). In addition, 
the afﬁnity of the autophosphorylated subunits for CaM increases, making it more 
sensitive to further calcium elevations (De Koninck and Schulman, 1998). These 
properties of CaM kinase II allow the enzyme to remain active for some time after 
calcium levels have dropped below activation threshold, which explains why CaM 
kinase  II  activity  is  stimulated  not  only  by  sustained  increases  in  calcium 
concentration but also by calcium oscillations (De Koninck and Schulman, 1998). 
The activity of CaM kinases I and IV, which act as monomeric enzymes, is also 
modulated  by  phosphorylation.  However,  in  contrast  to  CaM  kinase  II,  the 
regulatory  phosphorylation  events  are  catalysed  by a  distinct  group of  kinases 
termed CaM kinase kinases (CaMKK). Two CaMKK isoforms, a and b, have been 
cloned, and were found to be expressed in many tissues (including the nervous 
system) (Edelman et al., 1996; Tokumitsu et al., 1995). CaMKKs themselves are 
calcium/CaM-dependent enzymes. They phosphorylate calcium/CaM-bound CaM 
kinase  I  and  IV  on  a  threonine  residue  situated  within  the  activation  loop 
(threonine  residue  177  of  the  human  CaM  kinase  I  (Haribabu  et  al.,  1995); 
threonine residue 200 and 196 of the human and rat CaM kinase IV, respectively 
(Anderson et al., 1998; Selbert et al., 1995). These phosphorylation events cause 
the activity of CaM kinase I  and IV to increase several  folds.  Similar  to CaM 
kinase II, CaM kinase IV can autophosphorylate on serines 12 and 13, which is 
required  for  the  enzyme  to  be  active.  While  CaM kinase  IV is  predominantly 
nuclear (Jensen et al., 1991) and CaM kinase I appears to be a cytosolic enzyme 
(Picciotto et al., 1995), the subcellular distribution of CaM kinase II can vary. Four 
types  of  subunits  of  CaM kinase  II  have  been  identiﬁed  (a,  b,  g,  d)  that  are 
encoded by different genes with differing tissue-speciﬁc expression. Alternative 
splicing within the C-terminal sequence of each gene produces further isoforms. 
Although the biochemical  characteristics  of CaM kinase II  puriﬁed from many 
tissues are practically identical, the subunit composition, that is dependent on the 
source,  seems  to  determine  the  subcellular  localization  of  the  complex.  The 
regulatory domain of CaMKII is just distal to its catalytic domain and is bipartite: 
N-terminal  sequences  (aa  282-300)  are  believed  to  interact  with  the  catalytic 
domain to block both ATP (Colbran et al., 1989; Smith et al., 1992) and substrate 
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(Mukherji and Soderling, 1995) sites, whereas the C-terminal (aa 293-310) end 
binds  Ca2+/CaM.  The  overlap  of  these  subdomains  is  no  accident.  Binding  of 
Ca2+/CaM is the primary signal for release of autoinhibition. Current models of 
activation posit that the binding of Ca2+/CaM serves to disrupt the interactions of 
specific  residues  within  the  autoinhibitory  domain  with  the  catalytic  domain 
(Smith et al., 1992). In addition to relieving autoinhibition, binding of  Ca2+/CaM 
also  initiates  autophosphorylation  of  CaMKII,  providing  additional  layers  of 
regulation (figure 1.2). The first autophosphorylation site to be identified in the rat 
αCaMKII  was  Thr286.  Phosphorylation  of  this  site  occurs  as  an  inter-subunit 
reaction in the holoenzyme and requires  Ca2+/CaM binding to both the “kinase” 
and “substrate”  subunits  (Hanson et  al.,  1994).  This  site is  associated with the 
development  by  the  enzyme  of  Ca2+/CaM-independent  activity  (Miller  et  al., 
1988),  that never reaches the level attainable by the fully  Ca2+/CaM-stimulated 
enzyme,  but can be substantial and is important for synaptic and cell plasticity.  
Phosphorylation of Thr286 alters the interaction of the regulatory domain with the 
catalytic  core,  but  it  also  alters  the  interaction  of  the  kinase  with  Ca2+/CaM, 
causing its off-rate to fall by over three orders of magnitude (Meyer et al., 1992). 
This  results  in  a  phenomenon  that  has  been  termed  “CaM  trapping.”  Peptide 
models  of  trapping  suggested  that  autophosphorylation  induces  a  local 
conformational change that allows formation of additional, stabilizing interactions 
between CaM and Phe293 and Asn294 of CaMKII (Putkey and Waxham, 1996). 
Studies using CaMKII holoenzyme confirmed this model and showed that these 
residues  interact  with  specific  side  chains  in  the  C-terminal  domain  of  CaM 
(Singla et al., 2001). This ability of CaMKII to hang onto CaM long after calcium 
levels have fallen is integral to its ability to act as a neuronal frequency detector 
(Eshete  and Fields,  2001).  Indeed,  if  calcium levels  are  low for  long enough, 
Ca2+/CaM  will  dissociate  from  the  kinase.  Dissociation  makes  additional 
autophosphorylation sites in the regulatory domain available. Thr305 and Thr306, 
which are protected by bound Ca2+/CaM (Meador et al., 1993), can now undergo 
autophosphorylation  if  the  kinase  is  still  in  its  active,  pThr286,  state. 
Phosphorylation  of  these  additional  sites  prevents  rebinding  of  Ca2+/CaM  and 
maximal  activation of the kinase. Thr305/Thr306 have been called “inhibitory” 
sites,  but,  for  the  kinase  as  studied  in  vitro,  this  is  somewhat  of  a  misnomer 
because  only  kinase  that  is  constitutively  active  as  a  result  of  Thr286 
phosphorylation can become phosphorylated at  these sites at  a high rate.  Slow 
basal  phosphorylation  of  Thr306  occurs  in  the  absence  of  kinase  activation, 
presumably because of the proximity of this residue to the catalytic site (Colbran, 
1993) producing an enzyme that cannot be activated. As will be discussed below, 
there is  an additional  mechanism involving a CaMKII-binding protein that  can 
rapidly  mediate  phosphorylation  of  these  sites,  in  the  absence  of  pThr286,  to 
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produce an inhibited kinase that requires phosphatase to regain its ability to be 
stimulated by Ca2+/CaM. 
Figure 1.2 | CaMKII structural domains and regulation. 
CaMKII monomers consist of an N terminal catalytic domain and a C terminal association domain 
that bound a regulatory domain (top). The association domains (maroon circles) are required for 
assembly of the CaMKII monomers into the holoenzyme (middle panels). Under resting conditions 
the catalytic domain is constrained by the regulatory domain (left middle and bottom panels). After  
intracellular  Ca2+ rises  and  complexes  with  calmodulin  (CaM)  the  Ca2+/CaM  binds  to  the  C 
terminal portion of the CaMKII regulatory domain (mid portion of the top, middle and bottom 
panels)  to  prevent  autoinhibition  of  the  regulatory  domain  on  the  catalytic  domain,  activating 
CaMKII.  With sustained Ca2+/CaM or increased oxidation, CaMKII transitions into a Ca2+/CaM-
autonomous active enzyme after autophosphorylation (at Thr 287) or oxidation (at Met281/282) of 
amino acids in the regulatory domain. (Anderson et al.) 
Because  CaM  kinases  I,  II,  and  IV  have  quite  similar  substrate  specificity 
determinants, it is not completely surprising that they sometimes phosphorylate the 
same proteins. One substrate for all three of these kinases is the cAMP-response 
element  binding protein,  CREB. CREB is a ubiquitous transcription factor  that 
binds the cAMP-response element  (CRE) that was named owing to its original 
description as a target of cAMP-dependent protein kinase (PKA) (Shaywitz and 
Greenberg,  1999).  The  transcriptional  activity  of  CREB  is  regulated  by 
phosphorylation of S133, which promotes recruitment  of the transcriptional  co-
activator  CBP,  a  protein  that  displays  acetyltransferase  activity  towards  both 
histone  and other  transcriptional  regulatory proteins.  The phospho-CREB–CBP 
complex then interacts  with the basal transcriptional  apparatus  to initiate  RNA 
synthesis.  Subsequent  studies  showed  that  CREB can  be  phosphorylated  by  a 
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variety  of  kinases  including  PKA,  RSK,  RSK  1–3,  MSK,  MAPKAPK2  and 
p38MAPK.  CaMKI  and  IV  can  phosphorylate  the  activating  S133  of  CREB 
(Enslen et al., 1994; Sheng et al., 1991) and consequently, can markedly stimulate 
CRE-mediated transcription. The literature reveals that CaMKI is predominantly 
cytoplasmic (Picciotto et al., 1995) and the question as to whether it directly or 
indirectly  phosphorylates  CREB remains  controversial.  In contrast,  endogenous 
CaMKIV is present in the nucleus, and T cell experiments indicate that it could be 
a  relevant  CREB  kinase  for  interleukin-2  (IL-2)  production  (Anderson  et  al., 
1997). In addition to S133, CaMKII also phosphorylates S142, a modification that 
inhibits the transcriptional activity of CREB. Indeed, phosphorylation of Ser-142 
was not only inhibitory, but this modification was also dominant and could reverse 
the activation of CREB resulting from its phosphorylation on Ser-133 by PKA. 
This phosphorylation seems to be destabilizing for the association between CREB 
and CBP21. Interestingly, the nature of the effect of CaMKII on transcription is 
both cell and promoter dependent.
1.2 Arteriosclerosis and Ca2+ signalling
The physiological process of aging determines the replacement of the collagen in 
the  vessel  walls,  thus  modifying  their  thickness  and  elasticity.  These  changes 
determine medio-intimal hyperplasia, and are responsible for the isolated increase 
of  systolic  blood pressure above 140 mmHg in the elderly,  in  the presence of 
normal diastolic pressure (<90 mmHg). This physiological process can be sped up 
by risk factors such as hypertension, smoke, diabetes, dyslipidemia, and generate 
different clinical and morphological conditions. The histological phenomenon that 
precipitates arteriosclerosis the most is atherosclerosis, that is characterized by the 
lipid stuffing of the vessel walls, usually housed inside the inflammatory cells, as 
well  as  by  the  proliferation  of  the  vascular  smooth  muscle  cells,  with  the 
consequent  lumen  narrowing.  Conventionally,  the  atherosclerotic  plaque   is 
defined when the thickness of the vessel wall  is  above 1.3 mm. By definition, 
arteriosclerosis is an evolving condition, therefore without the removal of the risk 
factors sustaining it,  the atherosclerotic process progresses. Different stages can 
co-exist  at  different  stages  of  the  vascular  tree.  The  primum  movens  is  the 
activation of the endothelium, once considered just an internal lining of the vessel, 
and  characterized  by  a  terrific  endocrine  and  paracrine  potential.  Endothelial 
receptors  allow this structure to be affected by micro-environmental  variations, 
and change its phenotype: indeed, the endothelium can be either in a quiescent or 
in an activated state; the presence of risk factors induces its activation,  and the 
secretion  of  inflammatory  cytokines.  The  endothelium  then  exposes  adhesion 
molecules allowing the adhesion and localization of circulating monocytes; gaps 
open  and  the  tight  junctions  are  reduced,  to  facilitate  the  outgrowth  of  the 
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monocytes  from  the  blood  into  the  vessel’s  wall.  This  event  leads  to  the 
transformation of monocytes  into macrophages and dendritic cells, that on turn 
sustain the inflammation of the wall. Inflammatory cytokines (such as TNF, IL1, 
MCP-1), vaso-constrictor factors (Angiotensin, Endothelin, Cathecolamines), and 
pro-angiogenetic factors (VEGF, FGF) are released into the parietal  space,  and 
support both VSMC proliferation, and the metalloproteases that digest the collagen 
of the vessel’s wall. Therefore, the atherosclerotic plaque increases its volume due 
to the self-sustaining of the inflammatory events especially when the risk factors 
are  not  removed.  The  ongoing  inflammation  of  the  vessel’s  wall  leads  to 
degenerative events in the plaque, with the development of necrosis in the plaque’s 
core.  On  the  contrary,  when  the  risk  factors  are  removed,  the  inflammation 
reduces, and regenerative events prevail, thus leading to VSMC proliferation and 
calcium  deposition  in  the  intercellular  spaces.  Histologically,  the  plaque  can 
evolve either towards a stable plaque, or an unstable plaque. The prevalence of 
inflammatory  and  necrotic  events  leads  to  instability,  and  the  plaque  ulcers, 
generating blood clots. When the atherosclerosis involves the coronary arteries the 
case history of this condition corresponds to unstable angina and acute myocardial 
infarction, recently joined as acute coronary syndrome, whose symptoms are not 
induced  by  stress,  and  uprise  at  rest,  spontaneously,  due  to  its  thrombogenic 
nature. On the contrary, a stable plaque is less prone to ulcer, as it is made up by 
muscle cells, that are lined with newly forming endothelium, with a higher calcium 
component.  In this  case, the symptoms are due to the discrepancy between the 
capacity of the coronary flow to adequately perfuse the myocardium, and its need, 
especially  when  the  metabolic  demand  increases  (stress,  hypertensive  or 
tachycardia  attack).  Ca2+  is  involved  in  the  emergence  and  progression  of 
arteriosclerosis at different extents. Basic Ca2+  phosphate deposition underlies the 
development of arterial calcification, a frequent component of atherosclerosis. The 
body mass index, waist circumference, and visceral adipose tissue are associated 
with  subclinical  cardiovascular  disease,  as  well  as  with  abdominal  aortic 
calcification  (Fox et  al.,  2009),  and coronary  artery  calcium predicts  coronary 
artery disease events (Wong et al., 2009). Of note, inflammatory macrophages co-
localize with  Ca2+-phosphate deposits  in developing atherosclerotic  lesions,  and 
can  promote  calcification  through  the  release  of  TNFalpha.  Pathological 
calcification then is not merely a passive consequence of chronic inflammatory 
disease, but may lead to a positive feedback loop of calcification and inflammation 
driving disease progression. Ca2+ is a key signal transduction ion, and as such it is 
involved  in  the  pathogenesis  of  arteriosclerosis.  Indeed,  Ca2+ channel  blockers 
have the ability to retard or even reverse early atherosclerotic process (Ikeda et al., 
2009),  and its  role  concerns  all  cell  types  at  the basis  of  the process.  Chronic 
inflammation  is  the  pathogenetic  feature  of  atherosclerosis  and  cardiovascular 
disease mediated by angiotensin II, proinflammatory cytokines,  free fatty acids, 
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that promote the generation of reactive oxygen species (ROS) in vascular smooth 
muscle cells and endothelial cells, and mediate injury through several mechanisms 
involving  Ca2+  signaling.  Ca2+  is  a  pivotal  second  messenger  controlling  the 
activation of several immune cell  types.  Among the early critical  events taking 
place in arteriosclerosis, there is monocyte transendothelial extravasation, that is 
mediated by cell adhesion molecules and chemoattractants signaling inflammation 
or  injury  (Imhof  and  Aurrand-Lions,  2004).  The  recruited  mononuclear 
phagocytes accumulate at the inflammatory sites and terminally differentiate into 
macrophages  and  dendritic  cells  (DC)  (Murdoch  et  al.,  2004).  Local  hypoxia 
regulates the expression profile of the genes expressed by monocytes at various 
differentiation  stages,  and  promotes  the  switch  from a  pro-inflammatory  to  a 
migratory  phenotype.  The  distinct  steps  of  the  transendothelial  migration  are 
mediated by intracellular signals in the endothelium, that include changes in the 
intraendothelial free Ca2+ concentration. Indeed, the increase of the intraendothelial 
Ca2+  favours monocytes  extravasation (Kielbassa-Schnepp et  al.,  2001). CaMKs 
are  involved  in  the  regulation  of  monocyte  function  and  survival  to  different 
extent:  CaMKIV  regulates  survival  and  differentiation  of  DC  by  preventing 
accumulation  of  pCREB (Illario  et  al.,  2008),  whereas  CaMKII  is  involved in 
TNFa-induced  CD44 expression,  that  plays  a  pivoltal  role  in  the  migration  of 
immune cells (Mishra et al., 2005). Furthermore, the CaMKs could be involved in 
the  regulation  of  monocytes  through  the  tuning  of  the  extracellular-signal-
regulated  kinase  (ERK) pathway,  that  is  not  only  involved  in  the  proliferative 
events of arteriosclerosis. ERK inhibition indeed significantly reduced Monocyte 
chemotactic  protein-1  (MCP-1)-activated  ROS  generation,  where  MCP-1  is  a 
potent chemoattractant for monocytes. Transfection of an active mutant of MEK1 
(ERK 1/2 kinase) markedly increased superoxide production in rat aortic smooth 
muscle cells, suggesting that ERK 1/2 activation stimulates ROS generation (Lo et 
al.,  2005).  Among  the  cytokines  involved  in  monocyte  migration  is  IL 
(interleukin)-6:  ERK1/2  activation  is  crucial  for  IL-6-dependent  expression  of 
MCP-1, that plays a major role in atherosclerosis (Sobota et al., 2008), and ERK 
could be on turn regulated by the CaMKs pathway.  A relevant consequence of 
monocyte transmigration into the endothelial layer is the stimulation of endothelial 
proliferation,  that  is  another  feature  of  arteriosclerosis.  Monocyte-induced 
endothelial cell proliferation is accompanied by prolonged ERK activation and is 
inhibited by the specific ERK inhibitor PD98059. The contact-mediated effect of 
monocytes is specific to endothelial cells and does not occur with vascular smooth 
muscle  cells  (Schubert  et  al.,  2008).  In  the  atherosclerotic  process  typical  of 
arteriosclerosis,  the normally quiescent VSMC of the artery proliferate  into the 
intima,  and  specific  genetic  changes  take  place,  that  enhance  atherosclerosis 
(Komatsu et al., 1998). This phenomenon is referred to as neointimal hyperplasia, 
and is induced by agonists secreted by immune cells, platelets, VSMC themselves. 
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CaMKs  have  never  been  taken  into  account  while  looking  at  mechanisms  of 
atherosclerosis. It has recently been demonstrated that CaMKs regulate biological 
processes  that  are  relevant  to  the  process  of  atherosclerosis,  by  affecting  the 
biology  of  vascular  wall  cells  and  infiltrating  macrophages.  In  particular, 
CaMKIV plays a pivotal role in blood pressure regulation through the control of 
endothelial  nitric  oxide  synthase  activity  in  endothelial  cells  (Berridge  et  al., 
2000). Furthermore, a critical role for CaMKII has been demonstrated in VSMC 
proliferation  (Braun  and  Schulman,  1995;  Carafoli,  2002).  Finally,  CaMKs 
actively regulates chemiotaxis, diapedesis, chemokine production in macrophages 
and the survival program of dendritic cells (Hook and Means, 2001).
1.3 Plaque stability and instability: 
a balance between inflammation and repair
Atherosclerosis is currently the leading cause of death and disease in developed 
countries, soon to become the pre-eminent health problem worldwide (Murray and 
Lopez,  1997). It is  a progressive disease characterized by the accumulation of 
lipids and fibrous elements  in the large arteries and constitutes the single most 
important contributor to the growing burden of cardiovascular disease.
Atherosclerosis first involves a decades-long expansion of the arterial  intima, a 
normally small area between the endothelium and the underlying smooth muscle 
cells  of  the  media,  with  lipids,  cells,  and  extracellular  matrix.  Atherogenesis 
begins  with  the  subendothelial  retention  of  apolipoprotein  B-containing 
lipoproteins  in  focal  areas  of  the  arterial  subendothelium.  These  lipoproteins, 
following  oxidative  and  other  types  of  modification,  then  trigger  a  series  of 
maladaptive inflammatory responses. Key among these responses is the attraction 
of blood-borne monocytes to activated endothelial cells (ECs) overlying areas of 
lipoprotein retention, followed by monocyte differentiation into macrophages. The 
macrophages internalize the retained lipoproteins, leading to foam cell formation, 
and the macrophages become activated and inflammatory (Figure 1.3). Dendritic 
cells, T cells, mast cells, B cells, and possibly neutrophils also enter the growing 
lesion and contribute to the inflammatory response to retained lipoproteins.  As 
lesions develop, the inflammatory response amplifies and does not resolve, which 
is  likely a result  of the continuing and even accelerated  process of lipoprotein 
retention. As such, the subendothelial space expands with cells and extracellular 
matrix.  Although  this  process  itself  rarely  leads  to  major  symptoms  due  to 
preservation  of  the  arterial  lumen,  a  few  of  these  lesions  undergo  necrotic 
breakdown,  which  precipitates  acute,  occlusive  lumenal  thrombosis  and  its 
consequences: myocardial infarction, unstable angina (accelerating chest pain due 
to ongoing heart muscle ischemia), sudden cardiac death, and stroke (Virmani et 
al., 2002). 
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 Figure 1.3 | Progression of an Atherosclerotic Lesion
Early fatty streak lesions are characterized by the accumulation of apolipoprotein B-containing 
lipoproteins (apoB-LPs) in the subendothelial space, which incites the recruitment of dendritic cells 
and  macrophages.  As  the  atherosclerotic  lesion  progresses,  smooth  muscle  and  T  cells  also 
infiltrate the intima, and apoB-LP retention is amplified. Vulnerable plaques are characterized by 
the accumulation of apoptotic cells and defective phagocytic clearance (efferocytosis), resulting in 
the  lipid-filled  necrotic  core.  A  thinning  fibrous  cap  decreases  lesion  stability,  making  these 
atherosclerotic plaques susceptible to rupture and the formation of a thrombus. (Moore and Tabas)
A  principal  feature  of  inflammation  is  the  accumulation  of  leukocytes;  in 
longlasting  chronic  inflammatory  processes  these  leukocytes  are  macrophages, 
lymphocytes and mast cells. Basically the leukocytes have a protective function 
and  serve  in  host  defense  by  eliminating  injurious  agents,  but  their  secretory 
products may also augment injury by damaging surrounding tissue components. 
During inflammation  another  series  of events  is  initiated  that  must  lead to  the 
healing of injured tissue, either by regeneration or by scarring (fibrosis). Several 
studies pointed out that both inflammation and repair are key events in the natural 
course of atherosclerosis (Ross, 1993), and there is a great deal of evidence that 
inflammatory  cells  and  their  secretory  products  have  profound  effects  on  the 
integrity of the connective tissue meshwork of plaques (Libby, 1995). Most of the 
extracellular  matrix  components  of  a  plaque,  including  collagens,  elastin  and 
various types of proteoglycans are products of smooth muscle cells. Transforming 
growth factor beta (TGF-b) is one of the most potent stimulators of connective 
tissue production by smooth muscle cells. Large amounts of this growth factor are 
detected in restenosis lesions, and it also participates in the repair process after 
natural plaque disruption. Thrombin generated during episodes of local thrombosis 
is  another  stimulator  of  smooth  muscle  cell  growth.  TGF-b  and  other  growth 
factors,  including  platelet  derived  growth  factor  (PDGF)  and  basic  fibroblast 
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growth factor (bFGF), play an important role in wound healing and the reparative 
stage of many chronic inflammatory diseases. In the atherosclerotic plaque these 
growth factors  are  produced by ‘injured’  endothelial  cells  and macrophages  or 
released  from thrombus  (Ross,  1993). Smooth  muscle  proliferation  and matrix 
synthesis implies a mechanism of slowly progressive growth of plaques; it serves 
to encapsulate the soft atheroma and organizes episodes of thrombus formation, 
either  spontaneously  or  artificially  induced.  The  result  is  a  reparative  and 
stabilizing  effect  on  the  plaque  structure.  Activated  T-lymphocytes  and 
macrophages  produce  several  mediators  that  promote  destabilizing  effects  in 
plaques.  The  T-cell  cytokine  IFN-g  appears  to  play  an  important  role  in  this 
process,  by  inhibiting  the  proliferation  of  smooth  muscle  cells,  as  well  as 
decreasing  their  synthesis  of  collagen  fibrils.  Apoptosis,  an  intrinsically 
programmed mode of cell death, can be activated by inflammatory mediators, and 
is recognized as a mechanism of foam cell death in plaques. Cell death leads to the 
spill of lipids and, hence, the enlargement of the soft lipid core (Bjorkerud and 
Bjorkerud, 1996). Apoptosis of cells has been observed in atherosclerotic plaques 
and  in  restenosis  lesions.  In  early  and  restenosis  lesions,  smooth  muscle  cell 
apoptosis can have beneficial effects and promote regression, but in the fibrous 
cap of advanced lesions it introduces another potential of plaque destabilization 
through the loss of repair cells. In addition, during inflammation an even more 
powerful pathway of plaque desintegration is initiated by the extracellular matrix 
degrading  metalloproteinases  interstitial  collagenase  (MMP1),  stromelysin 
(MMP3)  and  the  gelatinases  MMP2  and  MMP9 (Galis  et  al.,  1994).  Once 
activated by plasmin or mast cell products, they initiate a cascade of proteolytic 
activities  with a very broad substrate  specificity,  including all  the extracellular 
matrix components of the fibrous cap. An observation of particular interest is that 
synthesis as well as lytic activity of these enzymes is most abundant in the lipid 
laden macrophages and in the extracellular space around lipid cores of plaques. 
There  are  several  arguments  in  support  of  a  correlation  between  lipids  and 
inflammation. First, during activation of the scavenging pathway for phagocytosis 
of oxidized lipoproteins, macrophages exert a number of secretory functions with 
detrimental  effect  on  the  plaque  tissue.  In  addition,  specific  T  cell  mediated 
immune responses appear to be involved in atherogenesis, and there is increasing 
evidence that a direct link may exist between accumulation of cholesterol in the 
vessel  wall  and  activation  of  T  cells,  possibly  by  autoimmune  responses  to 
modified  lipoproteins (Mitchinson  et  al.,  1990).  Therefore,  during  the  ongoing 
process of lesion formation,  and also in mature clinically relevant plaques, two 
major tissue remodeling forces may be operative. Smooth muscle cells increase the 
structural strength by producing the connective tissue matrix of a plaque. On the 
other  hand,  lipid  associated  inflammation  introduces  tissue  degrading  effects. 
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Whether a plaque tends to stability or instability will depend on which mechanism 
dominates the course of plaque formation in a given period of time (figure 1.4). 
Figure  1.4 |  Schematic  view of  the  two major  tissue  remodeling  forces  in  atherosclerotic  
plaques 
On the left side is a lipid-rich plaque. On the right  side is a fibrous plaque.  Arrow to the left  
indicates the destabilizing effects of lipids and inflammation, thus creating a vulnerable lipid-rich 
plaque. Arrow to the right indicates the reparative effects of smooth muscle cells, leading to the  
formation of a stable fibrous plaque (Allard C. van der Wal, 1998).
Any  process  that  decreases  the  synthesis  of  fibrous  cap  collagen  by  intimal 
fibromyoblast-like smooth muscle cells (SMCs) and/or contributes to cap collagen 
degradation  would  be  expected  to  promote  the  formation  of  plaques  prone  to 
rupture  (Figure  4).  Vulnerable  plaques  show  evidence  of  SMC  death  and 
decreased numbers of SMCs, and in vitro data show that macrophages can trigger 
apoptosis  in  SMCs by activating  their  Fas apoptotic  pathway and by secreting 
proapoptotic TNFa and nitric oxide (Boyle et al., 2003). Macrophages may also 
decrease collagen synthesis in intimal SMCs without actually killing the cells. For 
example,  in  regions  of  vulnerable  plaques  that  have  defective  clearance  of 
apoptotic cells, macrophage secretion of TGFb may be decreased, which would 
deprive neighbouring SMCs of this  important  inducer of collagen biosynthesis. 
Macrophage-derived matrix metalloproteinases (MMPs) may also be involved in 
thinning  of  the  fibrous  cap  (figure  1.5).  The  regulation  of  MMPs  by  athero-
relevant factors is complex, and it is influenced by transcriptional inducers and 
repressors  and by protease activators  and inhibitors.  Moreover,  once activated, 
certain  MMPs can activate  other  ones.  Studies  showing a temporal  and spatial 
correlation  between  the  presence  of  macrophages  in  rupture-prone  shoulder 
regions  of  plaques,  thinning  of  the  fibrous  cap  in  these  regions,  and  local 
accumulation of activated MMPs, especially MMP-2 and MMP-9, stimulated great 
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interest  in  the  potential  role  of  MMPs  in  plaque  rupture (Galis  et  al.,  1994). 
Observational data in vulnerable human plaques and the known biology of MMPs 
generated plausible hypotheses regarding the role of certain MMPs in fibrous cap 
thinning and plaque rupture. 
Figure 1.5 | Macrophages in Advanced Atherosclerotic Lesions
(1) Macrophage foam cells undergo apoptosis as a result of prolonged endoplasmic reticulum
 (ER) stress and other stimuli. (2) These apoptotic cells are not effectively cleared by macrophages 
(defective  efferocytosis)  in  advanced  lesions,  (3)  leading  to  secondary  cellular  necrosis.  (4) 
Secondary necrosis, over time, contributes to the formation of a necrotic core. (5) Smooth muscle 
cell death and protease degradation of the extracellular matrix weakens the fibrous cap, making it 
susceptible to rupture.  (6)  Exposure of  the thrombogenic  material  in  the lesion causes  platelet 
aggregation and thrombus formation. Also note that living macrophages in advanced plaques can 
contribute  to  vulnerable  plaque  formation  through  the  secretion  of  cytokines,  proteases,  and 
procoagulant/thrombotic factors (Moore and Tabas).
A second critical feature of dangerous plaques is their necrotic core (Figure 4), 
which contributes to inflammation, thrombosis, proteolytic plaque breakdown, and 
physical stress on the fibrous cap (Virmani et al., 2002). Necrotic cores arise from 
the  combination  of  apoptosis  of  advanced  lesional  macrophages  and defective 
phagocytic clearance (or efferocytosis) of the apoptotic macrophages in advanced 
plaques (Tabas).  This combination is  critical:  macrophage death also occurs in 
early atherosclerotic  lesions,  where efferocytic  clearance is  efficient,  leading to 
decreases in lesion cellularity, inflammation, and plaque progression rather than an 
increase  in  plaque  necrosis.  A  number  of  processes  in  advanced  lesions  may 
trigger macrophage death, and it is almost certain that a combination of factors and 
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processes  plays  a  role  in  vivo.  Examples  include  growth  factor  deprivation, 
oxidative stress, and death receptor activation by ligands that exist in advanced 
atheroma. Human and animal studies established that atherosclerosis is driven by a 
chronic inflammatory process within the arterial wall initiated mainly in response 
to  endogenously  modified  structures,  particularly  oxidized  lipoproteins  that 
stimulate both innate and adaptive immune responses (Tedgui and Mallat, 2006). 
The  innate  response  is  instigated  by  the  activation  of  both  vascular  cells  and 
monocytes/macrophages.  Subsequently,  an  adaptive  immune  response  develops 
against  an  array  of  potential  antigens  presented  to  effector  T  lymphocytes  by 
antigen-presenting cells. Vascular cells, endothelial cells (EC), and smooth muscle 
cells (SMC) participate in the development of the disease by mediating leukocyte 
recruitment  and  vascular  remodeling,  as  well  as  feeding  back  to  promote 
perpetuation of inflammation  through the release of proinflammatory cytokines 
and chemokines (figure 1.6).
Figure 1.6 | Cytokines involved in atherogenesis. 
Cytokines are produced by several cell types, including inflammatory and vascular cells, as well as  
adipocytes. IL-12 and IL-18 produced by macrophages are potent inducers of IFN- and promote the 
differentiation of naive T cells into proatherogenic Th1 cells. Macrophage or macrophage-derived 
cytokines also activate smooth muscle cells (SMC) and endothelial cells (EC) to produce an array 
of  proinflammatory  mediators.  On  the  other  hand,  the  anti-inflammatory  cytokines  IL-10  and 
TGF-,  also produced by macrophages,  promote  antiatherogenic  Treg  cell  differentiation.  Other 
anti-inflammatory  mediators  with  potent  antiatherogenic  properties  include  IL-1  receptor 
antagonist (IL-1ra) and IL-18 binding protein (IL-18BP). Interestingly, IL-4, the prototype of Th2 
cells, has proinflammatory properties on EC. Adipocytes produce both pro- and anti-inflammatory 
mediators. Leptin activates Th1 cells but inhibits Treg cell function. Adiponectin has been shown 
to dampen macrophage activation (Tedgui and Mallat, 2006).
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The biological  effects  of proinflammatory cytokines that  may account  for their 
proatherogenic  activity  are  multiple.  In  the  early  stages  of  atherosclerosis, 
cytokines can alter endothelial functions. Cytokines also induce the expression of 
chemokines and adhesion molecules on the vascular endothelium, thus favoring 
the recruitment, adherence, and migration of lymphocytes and monocytes into the 
inflamed vessel wall. Once in the intima, leukocytes can be permanently activated 
by  locally  generated  cytokines,  which  can  accelerate  the  transformation  of 
macrophages into foam cells by stimulating the expression of scavenger receptors 
and enhancing cell-mediated oxidation. At a more advanced stage of the disease 
(figure  1.7),  proinflammatory  cytokines  destabilize  atherosclerotic  plaques  by 
promoting cell apoptosis and matrix degradation. Macrophage apoptosis results in 
the formation of cell debris, which contributes to enlargement of the lipid core. 
Plaque SMC apoptosis leads to thinning in the fibrous cap, favoring its rupture 
(Clarke et al., 2006; Mallat and Tedgui, 2001; Tabas, 2005). 
Figure 1.7 | Effects of cytokines on atherosclerosis development and plaque destabilization.
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2. AIMS OF STUDY 
Atherosclerosis  is  a progressive,  multifactorial  chronic disease.  The initial  pro-
atherogenic process implicates upregulation of adhesion molecules on endothelial 
cells,  binding  of  low  density  lipoproteins  to  endothelium,  activation  of 
macrophages  and proliferation of vascular  smooth muscle cells.  It  has recently 
been  demonstrated  that  CaMKs  regulate  biological  processes  relevant  to 
atherosclerosis,  by  affecting  the  biology of  vascular  cell  walls  and infiltrating 
macrophages.  In  particular,  CaMKIV  plays  a  pivotal  role  in  blood  pressure 
regulation through the control of endothelial nitric oxide synthase activity (Santulli 
et  al,  2012).  A  critical  role  for  CaMKII  has  been  demonstrated  in  VSMC 
proliferation (Cipolletta et al, 2010; Abraham, 1997), and CaMKs actively regulate 
macrophage functions, as well as the survival program of dendritic cells (Illario et 
al, Blood 2008).
Aim of this doctorate thesis is to define the role of CaMKs in the atheroma 
mediated  inflammation,  and  investigate  whether  CaMKII  and  CaMKIV 
represent a suitable novel therapeutic target to prevent the emergence and 
progression of arteriosclerosis.
To this purpose I analyzed: 
Molecular characterization of stable and unstable plaques:
1. Patterns of CaMKs expression and activation to define a possible role in 
plaque formation and progression;
2. Differential role of CaMKs in resident and infiltrating vascular wall cell 
types: effects on proliferation and differentiation.
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3. RESULTS 
3.1 Expression of CaMKs mRNA transcripts in human atherosclerotic 
plaques
To  determine  the  expression  and  quantity  of   CaMKs  mRNA  in  human 
atherosclerotic  plaques,  a  SYBER  Green  real-time  PCR  was  performed  on  6 
unstable  atherosclerotic  plaques  and  6  stable  atherosclerotic  plaques.  The  data 
indicated a low expression of CaMKIV mRNA compared to CaMKII mRNA (A); 
in  particular  unstable  plaques  predominantly  express  CaMKIIγ  isoform  while 
stable plaques express mainly CaMKIIβ (B).
Figure 3.2 | Expression of CaMKs mRNA transcripts in human atherosclerotic plaques
SYBER Green real-time PCR analysis of CaMKs (A) and CaMKII isoforms (B) mRNA expression 
in unstable stable atherosclerotic plaques. Total RNA were extracted from human atherosclerotic 
plaques and reverse transcribed. The mRNA were analyzed by SYBER Green real-time PCR with 
specific  primers  to  CaMKs (CaMKII,  CaMKIV)  and  CaMKII  isoforms  (CaMKIIα,  CaMKIIβ, 
CaMKIIγ, CaMKIIδ)
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3.2 Expression of CaMKs in human atherosclerotic plaques
Western blot experiments were performed on protein extracts  from 10 unstable 
atherosclerotic plaques and 10 stable atherosclerotic plaques. CaMKII protein was 
highly expressed in all atherosclerotic plaques while there was no expression of 
CaMKV  protein  (A).  In  particular  CaMKII  is  highly  expressed  in  stable 
atherosclerotic  plaques  as  attested  the  densitometric  analysis  (B).  Furthermore, 
both plaque groups expressed high levels of CaMKIIγ and CaMKIIδ isoforms (B 
and D)
Figure 3.1 | Expression of CaMKs in human atherosclerotic plaques
Representative western blot showing expression of CaMKs in human atherosclerotic plaques (A). 
Significant expression of CaMKII was found in atherosclerotic plaques, in particular in the stable 
group (C). All atherosclerotic plaques expressed CaMKII gamma and delta isoforms (C and D)
Ponceau red staining is included to show total protein load.
19
CaMKIV
CaMKII
Ponceau red
Unstable
plaques
Stable
plaques
0
10
20
30
40
50
60
70
80
CaM
KII a
lfa
CaM
KII b
eta
CaM
KII g
amm
a
CaM
KII d
elta
C
aM
K
II 
is
of
or
m
s d
en
si
to
m
et
ry
 
-a
bs
ol
ut
e 
va
lu
es
-
stable plaques
unstable plaques
CaMKII alfa
CaMKII beta
CaMKII gamma
CaMKII delta
Ponceau red
Unstable
plaques
Stable
plaques
A
B D
0
20000
40000
60000
80000
100000
120000
CaMKII densitometry -
absolute values
-
stable plaques
unstable plaques
C
3.3 CaMKII activity in human atherosclerotic plaques
In order to define whether CaMKII was active in human atherosclerotic plaques a 
western blot experiment was performed. The western blot experiment showed high 
levels of CaMKII phosphorylation in stable plaques compared to unstable plaques 
(A and  B).  To  strongly  confirm CaMKII  activity  in  human  stable  plaques  an 
activity assay was performed.  The activity assay confirmed that CaMKII is more 
active in human stable plaques (C).
Figure 3.3 | CaMKII activity in human atherosclerotic plaques
Representative western blot showing activation of CaMKII  in human atherosclerotic plaques (A). 
Significant activation of CaMKII was found in atherosclerotic plaques, in particular in the stable 
group (B). This activation was confirmed by CaMKII activity assay (C) 
Ponceau red staining is included to show total protein load.
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3.4 Cellular localization of CaMKII in human atherosclerotic plaques
To determine the cell localization of CaMKII in human atherosclerotic plaques, 
immunofluorescence studies were performed on 6 human atherosclerotic plaques. 
As shown in Figure 3.4 (A), CaMKII was expressed mainly in F4/80 positive cells, 
a  marker  for  macrophages,  while  it  is  a  very  low  expression  in  VSMCs.  In 
addition, CaMKII is activated in atherosclerotic plaque macrophages (B).
Figure 3.3 | Cell localization of CaMKII in human atherosclerotic plaques
Representative  immunofluorescence  showing  CaMKII  expression  and  activation  in  human 
atherosclerotic plaques. Macrophages were identified by anti-F4/80 antibody while VSMCs were 
identified by anti- α-actin antibody.
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3.5 Macrophage conditioned medium modified CaMKs expression and 
activation in VSMCs
VSMCs  were  treated  for  24h  with  cellular  surnatant  of  cultured  macrophage 
extracted from human atherosclerotic plaques.  Macrophages conditioned medium 
treatment  induced  a  reduction  of  CaMKIIβ  isoform,  an  ex-novo expression  of 
CaMKIIγ and CaMKIIδ isoforms, while CaMKIIα isoform was undetectable; the 
treatment  had  no  effect  on  CaMKII  (A). CaMKII  activation  is  reduced  by 
macrophages  conditioned  medium  treatment  while  CaMKIV  expression  is 
increased following treatment (B).
Treatment of VSMC with macrophages conditioned medium induced a reduction 
of CaMKII activity (C).
Figure 3.5 | Macrophage conditioned medium modified CaMKs expression and activation in 
VSMCs
Representative western blot showing CaMKs expression and activation in VSMCs following the 
treatment with macrophage conditioned medium. The treatment modified CaMKs expression and 
activation (A and B). The result was supported by the results of  CaMKII activity assay (C).
22
CaMKIV
pCaMKII
Actin
CaMKII alfa
CaMKII beta
CaMKII gamma
CaMKII delta
CaMKII
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
C
PM VSMC
VSMC/macro CM
A
B
C
3.6 Macrophage conditioned medium reduce VSMCs proliferation
It was demostrated that CaMKII has a role on VSMC proliferation  (Cipolletta et 
al., 2010).
In  order  to  define  the  effect  of  macrophages  conditioned  medium  on  VSMC 
proliferation,  [3H]  thymidine incorporation  and  proliferation  assays  were 
performed. VSMCs proliferation and [3H] thymidine incorporation were strongly 
reduced by conditioned medium treatment.
 
Figure 3.6 | Macrophage conditioned medium reduce VSMCs proliferation
VSMCs were plated in 6-well plates and treated with cellular surnatant of cultured macrophage  
extracted from human atherosclerotic plaques for 24 hours. Following treatment, the medium was  
removed, cells detached from the plates, and counted (A). [3H] thymidine incorporation was used to 
measure DNA synthesis in VSMC cells treated with surnatant of cultured macrophage for 24 h (B).
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4. DISCUSSION AND CONCLUSIONS
I investigated the role of CaMKs in the inflammation process supporting atheroma, 
to  determine  whether  CaMKs  represent  a  suitable  novel  therapeutic  target  to 
prevent the formation and progression of human atherosclerotic plaques.
Atherosclerosis  is  an  inflammatory  disease:  identification  of  critical  regulatory 
pathways is important to improve the knowledge of its emergence and progression, 
to identify novel therapeutic pathways and to pave the way for novel therapeutic 
strategies to reduce its associated mortality.
Two  major  cell  types  are  present  in  the  atherosclerotic  plaque:  activated 
macrophages  and  VSMCs.  The  prevalence  of  one  cell  types  over  the  other 
participate in the fate of the atherosclerotic plaque towards stability or unstability. 
This study allows for the first time to better identify the intracellular signalling in 
the progression of atherosclerosis towards unstability.
Several  intracellular  signalling  pathways  are  involved  in  atherosclerosis 
development and progression.  Among these cascades, Ca2+  -mediated ones play a 
major role.  CaMKs are important transducers of changes in intracellular Ca2+  , 
and they regulate biological processes relevant to atherosclerosis, by affecting the 
biology of vascular cell walls and of infiltrating macrophages. 
In the first part  of my study I analyzed the patterns of CaMKs expression and 
activation in human atherosclerotic plaques, to define their possible role in plaque 
formation  and  progression.  The  plaques  samples  were  obtained  from  carotid 
endarteriectomy procedures,  and  were  classified  into  stable  plaques  group and 
unstable plaques group.
In  the  present  thesis  I  generated  data  demonstrating  that  CaMKII  is  highly 
expressed in atherosclerotic  stable plaques compared to atherosclerotic  unstable 
plaques,  whereas  CaMKIV  is  undetectable.  Furthermore,  all  atherosclerotic 
plaques mainly expressed CaMKII gamma and delta isoforms. 
I  subsequently  demonstrated  by  western  blot  analysis  that  CaMKII  is  highly 
phosphorylated in human atherosclerotic plaques. Indeed, as shown in the in vivo 
kinase assay, CaMKII is mainly active in the stable plaques group.
In  the  early  stages  of  atherosclerosis,  cytokines  alter  endothelial  functions, 
resulting  in  restructuring  of  the  intercellular  junctions,  and  leading  to  loss  of 
barrier  function,  thus facilitating leukocyte transmigration.  At a more advanced 
stage of the disease, proinflammatory cytokines destabilize atherosclerotic plaques 
by promoting cell apoptosis and matrix degradation. Macrophage apoptosis results 
in the formation of cell debris, which contribute to enlargement of the lipid core. 
Plaque SMC apoptosis leads to thinning of the fibrous cap, favouring its rupture 
(Ait-Oufella  et  al.).  Therefore,  living  macrophages  in  advanced  plaques  can 
contribute  to  vulnerable  plaque  formation  through  the  secretion  of  cytokines, 
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proteases,  and  procoagulant/thrombotic  factors.  Indeed,  the  prevalence  of 
inflammatory  and  necrotic  events  leads  to  instability,  and  a  role  for  CaMKII 
activation in VSMC was demonstrated (Cipolletta et al, 2010).  
Therefore, in the second part of  my study, I investigated the differential role of 
CaMKs in  resident  and infiltrating  vascular  wall  cell  types  and the  effects  on 
proliferation and differentiation.
First of all,  I confirm that stable and unstable plaques express different cellular 
types.  In particular prevalence of macrophages is observed in unstable plaques. 
This observation must be taken into consideration when comparing CaMKII and 
CaMKII isoforms expression and activity between the two kind of lesions.
I investigated CaMKII cellular localization in human atherosclerotic plaques. The 
immunofluorescence analysis showed that CaMKII is concentrated and activated 
in  macrophages  population,  while  it  is  very  poorly  expressed  in  the  vascular 
component of the atherosclerotic plaque.
Secondly, to define the effect of the inflammatory system on CaMKs expression 
and activation, a conditioned-medium model system was set-up. Treatment with 
macrophages  conditioned  medium  modified  CaMKs  expression  and 
phosphorylation  in  cultured  VSMCs.  The  treatment  induced  a  reduction  of 
CaMKII activity and of VSMCs proliferation, as shown in the proliferation assays.
This  finding  is  well  in  agreement  with  the  observation  of  increased  CaMKIV 
expression,  wich  is  only  present  in  VSMCs.  Indeed,  we  show  that  CaMKIV 
expression increases in the unstable atherosclerotic lesion as well as in VSMCs 
exposed to conditioned medium. This two findings together suggest that CaMKII 
and CaMKIV are counteregulated in proliferative cells. Although this has to be 
confirmed in other cell types. 
Cardiovascular diseases represent a leading cause of morbidity and mortality, with 
an  ever  increasing  burden  on  health  care  systems.  Acute  events  recognize 
atherosclerosis  as  the  common pathogenesis.  There  are  many evidences  in  the 
literature  on  the  cell  based  mechanisms  and  in  vivo  processes  involved  in 
atherosclerosis, that have been stimulated by the consideration that it is the leading 
cause of death in the industrialized world. The investigation of unstable plaque 
biology will help to identify novel therapeutic targets: so far, CaMKs have never 
been taken into account while looking at mechanisms of atherosclerosis.  It  has 
recently  been  demonstrated  that  CaMKs regulate  biological  processes  that  are 
relevant to the process of atherosclerosis, by affecting the biology of vascular wall 
cells and infiltrating macrophages (Santulli et al, 2012).
In summary with this elaborate I show:
1) Different  expression  of  CaMKII  in  VSMCs  and  macrophages  in 
atherosclerotic lesions
2) Abundance of macrophages in unstable atherosclerotic lesions causes 
reduced cell proliferation of VSMCs
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3) This latter phenomenon is accompanied by changes in CaMKII and 
CaMKIV expression in VSMCs
The  characterization  of  the  role  of  the  CaMKs  in  the  pathogenesis  of 
arteriosclerosis,  especially  in  the  inflammatory  and  proliferative  events 
determining its evolution, could provide a terrific opportunity to understand the 
molecular mechanism underpinning atherosclerotic plaque progression. My data 
pose  the  bases  of  new  therapeutic  strategies  based  on  the  cell  type  specific 
inhibition of CaMKII in macrophages for stabilization of atherosclerotic lesions
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5. MATERIALS AND METHODS 
5.1 Cell culture
The investigation conforms with the Guide for the Care and Use of Laboratory 
Animals  published  by U.S.  National  Institutes  of  Health  and  approved  by the 
Ethics Committee of the Federico II University. Primary cultures of VSMCs were 
obtained from thoracic aortas of WKY rats as described previously (Muthalif et 
al.,  1996).  VSMC  were  cultured  in  Dulbecco’s  minimal  essential  medium 
(BioWhittaker,  Virviers,  Belgium),  containing  10%  fetal  calf  serum  (GIBCO, 
Grand  Island,  NY,  USA),  200  mM  L-glutamine,  penicillin  (100  mg/ml)  and 
streptomycin (100 mg/ml).The plates were incubated at 37°C, in the presence of 
5% CO2.
Human  atherosclerotic  plaque  samples  of  carotid  were  obtained  from patients 
undergoing surgery for carotid stenosis.
To isolate macrophages from human atherosclerotic plaques were used magnetic 
beads bound to anti-CD14 antibody. The fresh tissue samples were transferred to a 
test tube containing sterile Hanks' balanced salts without Ca2+ and Mg2+ (Seromed, 
Biochrom KG). The tissues were washed from contaminating red blood cells and 
then dissected from adventitia The intima-media was cut into 1-mm3 pieces and 
then  incubated  in  a  proteolytic  solution  containing  450  U/mL  collagenase,  1 
mg/mL trypsin inhibitor,  and 4.8 mg/mL HEPES in Hanks'  balanced salts  in a 
siliconized  bottle  with a  magnetic  bar  stirring slowly at  37°C. Free cells  were 
collected every 10 to 15 minutes for up to 2 hours. Large fibers such as collagen 
and elastin were taken away by passing through a 100-mm mesh nylon filter and 
by incubating with 30 NL/mL uncoated magnetic beads for 10 minutes at 4°C. 
After washing, the cells were resuspended in RPMI 1640 supplemented with 1% 
BSA and incubated with 30 NL/mL CD14 beads (0.9 mg/mL) for 30 minutes at 
4°C. CD14-positive cells were collected with an magnetic particle concentrator. 
Unbound cells were washed away with Dulbecco's PBS containing 0.1% BSA
5.2 Western blot and immunoprecipitation procedures
The human atherosclerotic  plaques  and the VSMC  were lysed  on ice in RIPA 
buffer (50 mM Tris-HCl, pH 7.4,150 mM NaCl, 1% NP-40,2 mM EDTA,2 mM 
PMSF,  5  ug/mL  leupeptin, 5  ug/mL  pepstatin).The  lysate  were  quantified  by 
Biorad DC protein assay.  An equal  amount  of proteins  from each sample  was 
loaded with laemly buffer. Protein were resolved by SDS-PAGE and transferred to 
an Immobilion P membrane (Millipore Corporation, Bedford, MA). Membranes 
were blocked by incubation with PBS 0,2% tween , 5% nonfat dry milk  for one 
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hour at  room temperature.  The membranes were then incubated overnight with 
primary  antibodies  at  4°C,  washed for  40  minutes  with  PBS 0,2% tween  and 
incubated  for  1  hour  with  a  horseradish  peroxidase  -conjugated  secondary 
antibody. Finally, protein bands were detected by an enhanced chemiluminescence 
system (ECL, Amersham Bioscience). Computer-acquired images were quantified 
using ImageQuant software (Amersham Bio-sciences). 
Commercial  antibodies  were  diluted  1:1000  and  purchased  as  follows:  total 
CaMKII, actin, CaMKIIα, CaMKIIγ,CaMKIIδ (Santa Cruz); total CaMKIIβ and 
phosphoCaMKII (Zymed, Invitrogen), total CaMKIV (BD).
For immunoprecipitation assay the human atherosclerotic plaques and the VSMC 
were  lysed  in  immunoprecipitation  buffer  (50  mM  Tris-HCl,  pH  8.0,  5  mM 
EDTA, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycolate, 0.1% SDS, 
10  mM  NaF,  5  mM  EGTA,  10  mM  sodium  pyrophosphate,  and  1  mM 
phenylmethylsulfonylfluoride). 
Primary antibodies vs protein of interest and  Protein G plus/protein A agarose 
beads  (Oncogene  Science,  Boston,  MA)  were  used  to  immunoprecipitate 
corresponding proteins from 500 g of total lysate. Non immune rabbit IgG were 
used  as  control.  Rabbit  policlonal  antibody to  CaMKII were  from Santa  Cruz 
Biotechnology. 
5.3 CaMKII activity assay
In a first reaction step CaMKII was incubated for 30 minutes at 30 °C  with 5 mM 
CaCl2 and 5µM CaM in 50 µl of reaction mixture consisting of 50 mM HEPES 
pH  7.5,  10  mM  MgCl2,  0,5  mM  dithiothreitol  (DTT),  2µM  CaM,  100  nM 
microcystin, 0,5mM cold ATP .A 10 µl aliquot from the first reaction was than 
incubated  with  25mM  EGTA,  0,5  mM  Autocamtide  and  50  µM  ATP  (1500 
cpm/pmol [γ32P]ATP) in order to determine CaMKII autonomous activity on its 
peptide substrate Autocamtide. The reaction was carried out for 30 minutes at 30 
°C  and  20  µl  aliquots  of  the  reaction  mixture  were  spotted  onto  p81 
phosphocellulose filters (Upstate Biothechnology, Lake placid, NY) The level of 
[32P]  incorporation  into  Autocamtide  was  determined  by  liquid  scintillation 
counting.  Autocamtide  was  provided  by  prof.  P.  Campiglia  (University  of 
Salerno).
5.4 Cell proliferation and [3H]thymidine incorporation
VSMCs were plated in 6-well plates (50,000 cells/well) and treated with cellular 
surnatant of cultured macrophage extracted from  human atherosclerotic plaques 
for 24 hours. After treatment, the medium was removed, cells detached from the 
plates,  and counted.  To determine  DNA synthesis,  cells  were  plated  in  6-well 
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plate, and treated as described previously. 0.5 Ci [3H]thymidine were then added 
to the plates. After 24 h, the plates were gently washed with PBS, then with 10% 
trichloroacetic acid (TCA), and incubated 10 min with 20% TCA at 4°C. TCA was 
removed and cells were lysed with 0.2% SDS for 15 min at 4 C. The lysates were 
then resuspended in 5 ml scintillation fluid and counted in a  -counter (Beckton 
Dickinson).
5.5 Quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Total  RNA were extracted  from human atherosclerotic  plaques  with  a  RNeasy 
Lipid Tissue Mini Kit  (Qiagen) and reverse transcribed using a High Capacity 
Reverse Transcriptase Kit (Applied Biosystems). QRT-PCR was performed using 
a Bio-Rad IC5 thermo cycler (Bio-Rad Laboratories, Hercules, CA) using specific 
primers:
CaMKIV 5’-GGC ACA GGC TGA GCT GAT G-3’ forward 
                5’-CTA GTT CCA GGT CAG CCA CCT TT-3’ reverse 
CaMKII  5’-AAA CAG TCT CGT AAG CCC AG-3’ forward
               5’-ATC CCA TCT GTA GCG TTG TG-3’ reverse
CaMKIIα  5’-GAA GAG CGA TGG TGT GAA GA-3’ forward 
                  5’-ACT TTG GTG TCT TCA TCC TCG -3’ reverse 
CaMKIIβ  5’- CTC TCG CCA CAA TGT CTT CA  -3’ forward 
                  5’-CTG TCA GCC AGA GAT CAC CA -3’ reverse 
CaMKIIγ   5’-TCC GAG CCT CAC GTT CTA GT -3’ forward 
                  5’-CCG ACG ACT ACC AGC TCT TC -3’ reverse 
CaMKIIδ  5’-GGC TGC TGA GAA ATT CCT TG -3’ forward 
                  5’-ACT ATC AAC CCT GCC AAA CG -3’ reverse 
Cycle threshold (Ct) values from 3 independent experiments were normalized to 
the  internal  β-actin  control.  The ratio  of  fold change was calculated  using the 
Pfaffl method (Pfaffl 2001).
5.6 Immunofluorescence
Plaques obtained from  human carotid endarterectomy were fixed in formaline, 
embedded in paraffin and sectioned at 5 µm with a rotary microtome. Sections 
were dewaxed, rehydrated and incubated with anti-F4/80, CamKII, p-CamKII, α-
actin (SantaCruz) primary antibodies at a 1:50 dilution at room temperature for 
two  hours.  Specific  fluorescent  labeled  secondary  antibodies  (Alexa  Fluor, 
Invitrogen)  at a 1:100 dilution were incubated at room temperature for 1 hour. 
Images were taken by using an Eclipse E1000 Fluorescence Microscope (Nikon) 
and acquired by using Sigma Scan Pro software (Jandel). Images were optimized 
for contrast in Adobe PhotoShop, but no further manipulations were made. 
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5.7 Statistical analysis
Student’s t-test was used to assess statistical significance and a p-value <0.05 was 
deemed significant. Statistics were computed with GraphPad Prism software (San 
Diego, CA).
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